Artiva Biotherapeutics, Inc.
ARTV
$3.60
$0.020.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 251.00K | 2.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 0.00 | 251.00K | 2.60M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 0.00 | 0.00 | 251.00K | 2.60M |
| SG&A Expenses | 20.28M | 19.83M | 18.74M | 17.21M | 15.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.15M | 81.58M | 74.96M | 67.54M | 63.59M |
| Operating Income | -86.15M | -81.58M | -74.96M | -67.28M | -60.99M |
| Income Before Tax | -79.19M | -75.13M | -71.72M | -65.37M | -61.20M |
| Income Tax Expenses | -- | -- | -- | -- | 72.00K |
| Earnings from Continuing Operations | -79.19 | -75.13 | -71.72 | -65.37 | -61.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.19M | -75.13M | -71.72M | -65.37M | -61.28M |
| EBIT | -86.15M | -81.58M | -74.96M | -67.28M | -60.99M |
| EBITDA | -83.60M | -79.07M | -72.49M | -64.85M | -58.58M |
| EPS Basic | -3.25 | -3.29 | -24.41 | -40.82 | -54.99 |
| Normalized Basic EPS | -2.50 | -2.53 | -15.73 | -25.99 | -43.87 |
| EPS Diluted | -3.91 | -3.95 | -25.08 | -41.49 | -69.81 |
| Normalized Diluted EPS | -2.50 | -2.53 | -15.73 | -25.99 | -43.87 |
| Average Basic Shares Outstanding | 97.59M | 92.00M | 68.44M | 44.90M | 21.33M |
| Average Diluted Shares Outstanding | 97.59M | 92.00M | 68.44M | 44.90M | 21.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |